Dividend investing offers a reliable way to generate passive income, but the strategy often requires balancing between high-yield stocks and growth-focused dividend payers. On one hand, some stocks offer ultrahigh dividend yields, often with concerns about sustainability. On the other hand, low-yield stocks might focus on long-term growth and steady payout increases.
However, some companies offer the best of both worlds — strong yields paired with consistent dividend growth. For investors seeking dividend powerhouses for 2025, AbbVie (NYSE: ABBV) and W.P. Carey (NYSE: WPC) stand out as prime candidates. Here’s why they could be smart additions to your portfolio this year.
1. AbbVie: A Dividend Powerhouse with Growth Potential
AbbVie has established itself as a leading dividend growth stock since it spun off from Abbott Laboratories in 2013. Over the years, the pharmaceutical giant has increased its dividend payouts by an astonishing 310%. Despite this rapid growth, the stock still offers an impressive 3.6% dividend yield at current prices.
Recent Performance and Drug Portfolio Strength
While AbbVie faced recent challenges with its $8.7 billion acquisition of Cerevel Therapeutics, the long-term outlook remains promising. Cerevel’s experimental schizophrenia drug, Emraclidine, failed its Phase 2 trials, initially disappointing investors.
However, the company bounced back with a Phase 3 trial success for Tavapadon, a potential first-in-class Parkinson’s disease treatment. Positive results showed significant improvement in patient symptoms, positioning Tavapadon for blockbuster potential upon regulatory approval.
Blockbuster Drugs Driving Revenue
AbbVie’s growth isn’t solely reliant on Tavapadon. The company’s current blockbuster drugs continue delivering:
- Skyrizi (Psoriasis treatment): $7.9 billion in sales in the first nine months of 2024, a 48% increase year-over-year.
- Rinvoq (Arthritis treatment): $4.1 billion in sales over the same period, reflecting a 52% growth.
Both drugs, launched in 2019, have rapidly captured market share, supporting AbbVie’s revenue despite Humira’s patent expiry.
Dividend Safety and Cash Flow
AbbVie generates substantial cash flow, which strengthens its dividend sustainability:
- Free Cash Flow (FCF): $15.6 billion over the past 12 months.
- Dividend Payout Ratio: 70% of FCF, leaving ample room for reinvestment and future increases.
Why Buy AbbVie in 2025?
- Strong dividend history with consistent increases.
- New drug approvals boosting future growth.
- High free cash flow supporting dividend safety.
2. W.P. Carey: A High-Yield Real Estate Income Play
W.P. Carey (NYSE: WPC) is a leading real estate investment trust (REIT) with a focus on triple-net lease properties. Its diverse portfolio spans industrial, retail, and office spaces, making it a stable dividend payer in the REIT sector.
Consistent High-Yield Dividend Payer
W.P. Carey currently offers a dividend yield exceeding 6%, positioning it among the best high-yield stocks in the market. Its quarterly payouts have steadily increased for over two decades, even during economic downturns.
Diversified Property Portfolio
The REIT’s strength lies in its geographically diverse and sector-diverse portfolio:
- Over 1,400 properties across 25 countries.
- Focus on industrial (31%), warehouse (25%), and retail (20%) sectors.
This diversification reduces risk and provides steady rental income, even during market volatility.
Defensive Business Model: Triple-Net Leases
W.P. Carey uses a triple-net lease structure, where tenants cover:
- Property taxes
- Maintenance costs
- Insurance expenses
This strategy limits operational risk and ensures consistent cash flow, allowing the company to maintain its high dividend payouts.
Financial Health and Dividend Coverage
- Adjusted Funds from Operations (AFFO): $5.46 per share (2024 projection).
- Dividend Payout Ratio: Approximately 80%, in line with REIT standards.
W.P. Carey’s financial strength and triple-net lease structure provide predictable cash flow, ensuring dividend stability for income-focused investors.
Why Buy W.P. Carey in 2025?
- High yield (6%+) for passive income seekers.
- Defensive triple-net lease model.
- Long history of dividend increases.
Key Takeaways: AbbVie vs. W.P. Carey — Which Is Better?
Both AbbVie and W.P. Carey offer compelling reasons for dividend investors:
| Criteria | AbbVie (ABBV) | W.P. Carey (WPC) |
|---|---|---|
| Dividend Yield | 3.6% | 6%+ |
| Dividend Growth | 310% since 2013 | Consistent, smaller increases |
| Dividend Safety | Strong FCF, 70% payout ratio | Stable AFFO, 80% payout ratio |
| Growth Potential | New drug approvals (Skyrizi, Tavapadon) | Expanding property portfolio |
| Risk Factors | Patent expirations, R&D risks | Interest rate sensitivity, occupancy |
Best for Growth and Dividend Growth:
- AbbVie (ABBV) with its rapidly growing pharmaceutical pipeline.
Best for High Yield and Stability:
- W.P. Carey (WPC) due to its defensive triple-net lease model.
Final Verdict: Why Not Own Both?
For dividend investors, a combination of AbbVie and W.P. Carey offers a balanced income strategy. AbbVie provides dividend growth potential supported by blockbuster drugs, while W.P. Carey offers high yield stability with its diversified REIT model.
Both stocks present compelling income-generating opportunities for 2025 and beyond, making them strong candidates for long-term portfolios.
For the latest Business and Finance News, subscribe to Globalfinserve.